ATE524067T1 - Zusammensetzungen und verfahren zur behandlung von zns-schäden - Google Patents

Zusammensetzungen und verfahren zur behandlung von zns-schäden

Info

Publication number
ATE524067T1
ATE524067T1 AT04752310T AT04752310T ATE524067T1 AT E524067 T1 ATE524067 T1 AT E524067T1 AT 04752310 T AT04752310 T AT 04752310T AT 04752310 T AT04752310 T AT 04752310T AT E524067 T1 ATE524067 T1 AT E524067T1
Authority
AT
Austria
Prior art keywords
injury
compositions
methods
functions
nervous system
Prior art date
Application number
AT04752310T
Other languages
English (en)
Inventor
Elliott Gruskin
Anthony Caggiano
Michael Zimber
Andrew Blight
Original Assignee
Acorda Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acorda Therapeutics Inc filed Critical Acorda Therapeutics Inc
Application granted granted Critical
Publication of ATE524067T1 publication Critical patent/ATE524067T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A61K9/122—Foams; Dry foams

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Lubricants (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT04752310T 2003-05-16 2004-05-17 Zusammensetzungen und verfahren zur behandlung von zns-schäden ATE524067T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47123603P 2003-05-16 2003-05-16
PCT/US2004/015253 WO2004103299A2 (en) 2003-05-16 2004-05-17 Compositions and methods for the treatment of cns injuries

Publications (1)

Publication Number Publication Date
ATE524067T1 true ATE524067T1 (de) 2011-09-15

Family

ID=33476545

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04752310T ATE524067T1 (de) 2003-05-16 2004-05-17 Zusammensetzungen und verfahren zur behandlung von zns-schäden

Country Status (10)

Country Link
US (3) US20080025963A1 (de)
EP (2) EP2353606B1 (de)
JP (2) JP4754492B2 (de)
AT (1) ATE524067T1 (de)
AU (1) AU2004241088B2 (de)
CA (1) CA2525804C (de)
ES (2) ES2420510T3 (de)
MX (1) MXPA05012305A (de)
PL (1) PL1631234T3 (de)
WO (1) WO2004103299A2 (de)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE500842T1 (de) 2002-05-04 2011-03-15 Acorda Therapeutics Inc Zusammensetzungen und verfahren zur förderung des neuronalen wachstums
EP3211084B1 (de) 2003-05-16 2019-03-27 Acorda Therapeutics, Inc. Proteoglycan-abbauende mutanten zur behandlung des zns
US7959914B2 (en) 2003-05-16 2011-06-14 Acorda Therapeutics, Inc. Methods of reducing extravasation of inflammatory cells
AU2005244933B2 (en) * 2004-05-18 2011-08-04 Acorda Therapeutics, Inc. Methods of purifying chondroitinase and stable formulations thereof
JP2006232754A (ja) * 2005-02-25 2006-09-07 Gi Biopolis:Kk 消化管粘膜切除後の消化管潰瘍治癒促進用スプレー剤
JP5189985B2 (ja) * 2005-09-26 2013-04-24 アコーダ セラピューティクス、インク． コンドロイチナーゼａｂｃｉ変異体を用いた組成物およびその使用方法
AU2007299738B2 (en) 2006-09-20 2013-03-28 The Board Of Regents Of The University Of Texas System Methods for delivering volatile anesthetics for regional anesthesia and/or pain relief
TW200817015A (en) * 2006-10-06 2008-04-16 Hen-Rich Cheng A method for promoting axonal re-growth and behavior recovery in spinal cord injury
AU2016206267B2 (en) * 2006-10-10 2018-07-05 Acorda Therapeutics, Inc. Compositions and methods of using chondroitinase abci mutants
AU2014200000B2 (en) * 2006-10-10 2016-04-21 Acorda Therapeutics, Inc. Compositions and methods of using chondroitinase abci mutants
US7722864B2 (en) 2006-10-10 2010-05-25 Acorda Therapeutics, Inc. Compositions and methods of using chondroitinase ABCI mutants
WO2008149428A1 (ja) * 2007-06-05 2008-12-11 Glycoscience Laboratories, Inc. 自己免疫疾患、炎症及び神経疾患の治療剤及び予防剤
US20110059508A1 (en) 2007-06-29 2011-03-10 National University Corporation Nagoya University Improving agent for dysfunction due to neuropathy and rho kinase activation inhibitor
US8198083B1 (en) 2007-10-31 2012-06-12 William Gunter Loudon Organotypic slices of the central nervous system
EP3581169A1 (de) 2008-01-22 2019-12-18 The Board Of Regents Of The University Of Texas System Flüchtige anästhesiemittelzusammensetzungen mit extraktiven lösungsmitteln für lokale anästhesie und/oder schmerzlinderung
US20110275137A1 (en) * 2008-04-14 2011-11-10 Seikagaku Corporation Improving agent for neuropathic pain
EP2153844A1 (de) * 2008-08-14 2010-02-17 HAUBECK, Hans-Dieter Humane Hyaluronidasen zum erneuten axonalen Wachstum
WO2012136768A1 (en) 2011-04-08 2012-10-11 Hans-Dieter Haubeck Use of mutants of human hyaluronidase ph-20 with increased chondroitinase activity for axonal regrowth
WO2014202834A1 (en) 2013-06-18 2014-12-24 University Of Helsinki Protamine in treatment of neuronal injuries
CN108795918A (zh) * 2018-07-18 2018-11-13 北京电子科技职业学院 一种外切型硫酸软骨素酶abc及其制备方法与应用

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270194A (en) * 1989-08-31 1993-12-14 Instrumentation Laboratory Spa Stabilized glucose oxidase from Aspergillus Niger
US5804604A (en) * 1989-12-21 1998-09-08 Biogen, Inc. Tat-derived transport polypeptides and fusion proteins
US5747641A (en) * 1989-12-21 1998-05-05 Biogen Inc Tat-derived transport polypeptide conjugates
US5679650A (en) * 1993-11-24 1997-10-21 Fukunaga; Atsuo F. Pharmaceutical compositions including mixtures of an adenosine compound and a catecholamine
US5262522A (en) * 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
US5496718A (en) * 1992-06-26 1996-03-05 Seikagaku Kogyo Kabushiki Kaisha (Seikagaku Corporation) Chondroitinase ABC isolated from proteus vulgaris ATCC 6896
US7008783B1 (en) * 1992-09-22 2006-03-07 Maruha Corporation Gene encoding chondroitinase ABC and uses therefor
US5578480A (en) * 1993-04-23 1996-11-26 American Cyanamid Company Methods for the isolation and purification of the recombinantly expressed chondroitinase I and II enzymes from P. vulgaris
US6248562B1 (en) * 1993-11-01 2001-06-19 Research Foundation State University Of New York Chimeric proteins comprising borrelia polypeptides and uses therefor
US5498536A (en) * 1994-04-22 1996-03-12 American Cyanamid Company Chondroitinase II from Proteus vulgaris
US6093563A (en) * 1994-07-08 2000-07-25 Ibex Technologies R And D, Inc. Chondroitin lyase enzymes
US5997863A (en) 1994-07-08 1999-12-07 Ibex Technologies R And D, Inc. Attenuation of wound healing processes
US6326166B1 (en) * 1995-12-29 2001-12-04 Massachusetts Institute Of Technology Chimeric DNA-binding proteins
US5792743A (en) * 1995-04-19 1998-08-11 Acorda Therapeutics Method for promoting neural growth comprising administering a soluble neural cell adhesion molecule
US6313265B1 (en) * 1995-07-24 2001-11-06 The Scripps Research Institute Neurite outgrowth-promoting polypeptides containing fibronectin type III repeats and methods of use
US5869301A (en) * 1995-11-02 1999-02-09 Lockhead Martin Energy Research Corporation Method for the production of dicarboxylic acids
AU6897198A (en) * 1997-04-11 1998-11-11 Beth Israel Deaconess Medical Center Use of chondroitinase in the manufacture of a medicament in the treatment and prevention of mucoid secretions
EP0875253B1 (de) * 1997-05-02 2005-04-06 Seikagaku Corporation Chondroitinase enthaltende Zusammensetzungen
DK0900569T3 (da) * 1997-08-22 2003-01-27 Seikagaku Kogyo Co Ltd Terapeutisk middel til behandling af herniaramt intervertebral diskus
US6153187A (en) * 1997-09-02 2000-11-28 Insight Strategy & Marketing Ltd. Use of glycosaminoglycans degrading enzymes for management of airway associated diseases
AU3006899A (en) * 1998-03-13 1999-09-27 Biomarin Pharmaceutical Inc. Carbohydrate-modifying enzymes for burn and wound debridement and methods for treatment
US6171575B1 (en) * 1998-04-06 2001-01-09 Shinichi Okuyama Method of radioisotopic assessment of the integrity and function of the nose-brain barrier
WO2000012726A2 (en) * 1998-08-27 2000-03-09 Massachusetts Institute Of Technology Rationally designed heparinases derived from heparinase i and ii
ATE342961T1 (de) * 1998-10-06 2006-11-15 Univ Rush Medical Center Zusammensetzung zur verwendung in der chemonukleolyse
US5932563A (en) * 1998-10-23 1999-08-03 Ohio State Research Foundation Methods for treating spinal cord injury
EP1263459A2 (de) * 1999-12-02 2002-12-11 Ibex Technologies, Inc. Verminderung der fibroblasten proliferation
WO2003000901A2 (en) * 2001-06-26 2003-01-03 Decode Genetics Ehf. Nucleic acids encoding protein kinases
KR20040021697A (ko) * 2001-08-13 2004-03-10 유니버시티 오브 플로리다 리서치 파운데이션, 인크. 신경 조직 복구를 증진시키는 물질 및 방법
GB0205022D0 (en) * 2002-03-04 2002-04-17 Univ Cambridge Tech Materials and methods for the treatment of cns damage
ATE500842T1 (de) * 2002-05-04 2011-03-15 Acorda Therapeutics Inc Zusammensetzungen und verfahren zur förderung des neuronalen wachstums
DE60334220D1 (de) * 2002-06-03 2010-10-28 Massachusetts Inst Technology Rationell konstruierte, von chondroitinase b abgeleitete lyasen
US7163545B2 (en) * 2002-07-29 2007-01-16 Mayo Foundation For Medical Education And Research Spinal cord surgical implant
US7074581B2 (en) * 2002-08-09 2006-07-11 Sysmex Corporation Reagent for assaying lipid
BR0313331A (pt) * 2002-08-10 2007-07-24 Univ Yale antagonistas de receptor de nogo
WO2004017044A2 (en) * 2002-08-15 2004-02-26 Acorda Therapeutics, Inc. Chimeric protein
WO2004060146A2 (en) * 2002-12-30 2004-07-22 Purdue Research Foundation Method of treatment for central nervous system injury
US7959914B2 (en) * 2003-05-16 2011-06-14 Acorda Therapeutics, Inc. Methods of reducing extravasation of inflammatory cells
EP3211084B1 (de) * 2003-05-16 2019-03-27 Acorda Therapeutics, Inc. Proteoglycan-abbauende mutanten zur behandlung des zns
EP1737954A2 (de) * 2004-03-10 2007-01-03 The Massachusetts Institute Of Technology Rekombinante chondroitinase abc i und verwendungen davon
JP5189985B2 (ja) * 2005-09-26 2013-04-24 アコーダ セラピューティクス、インク． コンドロイチナーゼａｂｃｉ変異体を用いた組成物およびその使用方法

Also Published As

Publication number Publication date
EP2353606B1 (de) 2013-04-17
EP1631234A2 (de) 2006-03-08
PL1631234T3 (pl) 2012-02-29
EP1631234B1 (de) 2011-09-14
US20080025963A1 (en) 2008-01-31
WO2004103299A8 (en) 2005-03-31
WO2004103299A2 (en) 2004-12-02
CA2525804C (en) 2017-04-25
US20200016247A1 (en) 2020-01-16
JP4754492B2 (ja) 2011-08-24
JP5432113B2 (ja) 2014-03-05
ES2420510T3 (es) 2013-08-23
EP1631234A4 (de) 2008-11-19
AU2004241088B2 (en) 2010-08-05
JP2007520447A (ja) 2007-07-26
ES2373039T3 (es) 2012-01-30
EP2353606A2 (de) 2011-08-10
US20140248253A1 (en) 2014-09-04
CA2525804A1 (en) 2004-12-02
WO2004103299A3 (en) 2008-01-24
JP2011126880A (ja) 2011-06-30
MXPA05012305A (es) 2006-04-18
AU2004241088A1 (en) 2004-12-02
EP2353606A3 (de) 2011-08-31

Similar Documents

Publication Publication Date Title
ATE524067T1 (de) Zusammensetzungen und verfahren zur behandlung von zns-schäden
AU2003273171A8 (en) Immunomodulatory compounds and methods of use thereof
ATE490786T1 (de) Behandlung von verletzungen des zentralen nervensystems
DE602006016934D1 (de) Verfahren und zusammensetzungen zur behandlung von zns-erkrankungen
WO2005039504A3 (en) Compounds and methods for treating toll-like receptor 2-related diseases and conditions
ATE522229T1 (de) Anti-ngf-antikörper zur behandlung verschiedener erkrankungen
ATE362361T1 (de) Verfahren zur behandlung vaskulärer kopfschmerzen
DE60034871D1 (de) Verfahren und zusammensetzungen zur prevention oder behandlung von krebs und von krebs assoziertem knochenverlust
ATE411016T1 (de) Verfahren zur prophylaxis oder behandlung von östrogen-abhängigen krankheiten
ATE555803T1 (de) Verwendung von osteopontin zur behandlung und/oder vorbeugung von neurologischen erkrankungen
WO2005081619A3 (en) Compounds and methods for increasing neurogenesis
MY118414A (en) Use of substituted aminomethyl-chromans for the prevention of neuronal degeneration and for the promotion of neuronal regeneration
ATE526980T1 (de) Zusammensetzungen und verfahren zur heilung von nervengeweben
DE60336341D1 (de) Zusammensetzungen und verfahren zur förderung des neuronalen wachstums
PL376149A1 (en) Piperazine and piperidine derivatives for treatment of neurological diseases
MX349462B (es) Composiciones y metodos para el tratamiento de lesiones del snc.
ATE334174T1 (de) System und prozess zur reinigung und/oder behandlung von fahrzeugoberflächen
DE602006015373D1 (de) Zusammensetzungen und Verfahren zur Prävention und Behandlung von immunvermittelten Entzündungskrankheiten
ATE380551T1 (de) Verwendung von brimonidine zur behandlung von dementia und morbus parkinson
HUP0002318A1 (hu) Eljárás idegregenerálódás serkentésére
GB0511698D0 (en) Compositions and method for treating affective, painful or allergic disorders
ATE361079T1 (de) Verwendung von pyrimidinnukleotiden zur behandlung von schaedigungen des peripheren nervensystems
ATE526954T1 (de) Atomoxetin zur behandlung von allergischer rhinitis und asthma
WO2004112721A3 (en) Prevention or treatment of deficits that arise in connection with diseases of, or injuries to, the nervous system
IL157708A0 (en) Composition and method for treatment or prevention of central nervous system disorders

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties